Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.58 |
| ▸ | CNR2 | P34972 | 2/20 | 0.58 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.34 |
| ▸ | SMO | Q99835 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14545456 | 0.87 | CNR1 (0.62) | CNR1CNR2PTPN11SMO | |
| SCHEMBL14545441 | 0.81 | CNR1 (0.62) | CNR1CNR2PTPN11SMO | |
| SCHEMBL14544965 | 0.81 | CNR1 (0.67) | CNR1CNR2JAK2JAK1JAK3 | |
| SCHEMBL14545384 | 0.80 | CNR1 (0.77) | CNR1CNR2PTPN11SMO | |
| SCHEMBL14544955 | 0.79 | CNR1 (0.65) | CNR1CNR2PTPN11 | |
| SCHEMBL14545183 | 0.78 | CNR1 (0.54) | CNR1CNR2PTPN11PDE2APDE10A | |
| SCHEMBL14545302 | 0.78 | CNR1 (0.80) | CNR1CNR2PTPN11 | |
| SCHEMBL14544944 | 0.77 | CNR1 (0.78) | CNR1CNR2PDE10A | |
| SCHEMBL14545587 | 0.77 | CNR1 (0.44) | CNR1CNR2CDC7DBF4PTPN11 | |
| SCHEMBL14545613 | 0.77 | CNR1 (0.72) | CNR1CNR2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885CDC7 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.